Zenas BioPharma, Inc.
ZBIO
$32.34
-$0.71-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | 46.22% | 73.10% | 13.35% | 2.60% | 27.27% |
| Gross Profit | -43.89% | -142.58% | -26.19% | -2.60% | -27.27% |
| SG&A Expenses | 29.75% | 36.21% | 35.98% | 76.79% | 105.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.59% | 63.43% | 17.63% | 16.09% | 38.94% |
| Operating Income | -40.78% | -107.21% | -28.21% | -16.09% | -38.94% |
| Income Before Tax | -113.29% | -139.76% | -360.63% | -33.40% | -37.46% |
| Income Tax Expenses | 470.00% | -- | -75.29% | -- | -- |
| Earnings from Continuing Operations | -113.42% | -141.23% | -357.08% | -33.40% | -37.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.42% | -141.23% | -357.08% | -33.40% | -37.51% |
| EBIT | -40.78% | -107.21% | -28.21% | -16.09% | -38.94% |
| EBITDA | -40.80% | -107.32% | -28.26% | -16.17% | -39.03% |
| EPS Basic | -41.57% | -81.27% | -261.63% | 75.64% | 94.85% |
| Normalized Basic EPS | -3.36% | -80.20% | -11.70% | 78.01% | 94.85% |
| EPS Diluted | -41.57% | -81.27% | -261.63% | 75.64% | 94.85% |
| Normalized Diluted EPS | -3.36% | -80.20% | -11.70% | 78.01% | 94.85% |
| Average Basic Shares Outstanding | 50.75% | 33.07% | 26.39% | 447.69% | 2,571.18% |
| Average Diluted Shares Outstanding | 50.75% | 33.07% | 26.39% | 447.69% | 2,571.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |